安科生物 reported revenue of ¥1.10B for the period ended 2026-06-30, -15.0% year on year. Net income was ¥0.34B, a 31.0% net margin on a 75.8% gross margin. The largest revenue line is 基因工程药 at 74% of the total. Free cash flow for the period was ¥0.11B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.10B | -15.0% |
| Gross profit | ¥0.83B | — |
| Operating income | ¥0.39B | — |
| Net income | ¥0.34B | -9.1% |
| Gross margin | 75.8% | Net margin 31.0% |
| Revenue Q/Q | +2.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 基因工程药 | ¥0.82B | 74.3% |
| 其他主营业务 | ¥0.20B | 18.0% |
| 外用贴膏 | ¥0.08B | 7.4% |
| 其他(补充) | ¥0.00B | 0.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.27B | 24.2% |
| R&D | ¥0.08B | 7.1% |
| SG&A | ¥0.37B | 33.7% |
| Tax & other | ¥0.05B | 4.7% |
| Item | Amount |
|---|---|
| Total assets | ¥5.13B |
| Total liabilities | ¥0.71B |
| Shareholders' equity | ¥4.41B |
| Equity / assets | 86.1% |
| Operating cash flow | ¥0.13B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.11B |
| Cash conversion (OCF / net income) | 80% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
ST豆神 ・ 鼎汉技术 ・ 华测检测 ・ 新宁物流 ・ 北陆药业 ・ 网宿科技 ・ 中元股份 ・ 硅宝科技 ・ ST银江 ・ 大禹节水 ・ 吉峰科技 ・ 机器人
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies